DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAC2. A total of 11 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$105,134,820
+11.8%
98,354,0000.0%2.32%
+15.3%
Q2 2023$94,044,128
-7.1%
98,354,0000.0%2.01%
-11.0%
Q1 2023$101,202,725
+6.3%
98,354,0000.0%2.26%
+14.5%
Q4 2022$95,235,195
+17.4%
98,354,000
+25.3%
1.97%
+22.1%
Q3 2022$81,098,00078,500,0001.61%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2022
NameSharesValueWeighting ↓
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 98,354,000$105,134,8202.32%
CSS LLC/IL 4,500,000$4,831,1730.32%
WOLVERINE ASSET MANAGEMENT LLC 7,792,000$8,378,0830.09%
CITIGROUP INC 262,000$280,4970.00%
JPMORGAN CHASE & CO 175,000$187,6880.00%
JANE STREET GROUP, LLC 60,000$64,2190.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders